Nelfinavir

Generic Name: Nelfinavir

Brand Names: Viracept

Drug Type: Small Molecule

Chemical Formula: C_₃₂H_₄₅N_₃O_₄S

CAS Number: 159989-64-7

Unique Ingredient Identifier: HO3OGH5D7I

Background: Nelfinavir is a potent HIV-1 protease inhibitor. It is used in combination with other antiviral drugs in the treatment of HIV in both adults and children. Nelfinavir inhibits the HIV viral proteinase enzyme which prevents cleavage of the gag-pol polyprotein, resulting in noninfectious, immature viral particles.

Indication: Used in combination with other antiviral drugs in the treatment of HIV in both adults and children.

Associated Conditions: Human Immunodeficiency Virus Type 1 (HIV-1) Infection

Associated Therapies: -

Clinical Trials

Nelfinavir, a Phase I/Phase II Rectal Cancer Study

Phase 1

Completed

Conditions: Colorectal Carcinoma
Colorectal Tumors
Neoplasms, Colorectal
Colorectal Cancer

Interventions: Drug: nelfinavir

First Posted Date: 2008-06-25

Last Posted Date: 2014-12-08

Lead Sponsor: Maastricht Radiation Oncology

Target Recruit Count: 15

Registration Number: NCT00704600

Locations: 🇳🇱
Maastro clinic, Maastricht, Netherlands

Study With Nelfinavir and Combined Radiochemotherapy for Glioblastoma

Phase 1

Completed

Conditions: Glioblastoma

Interventions: Drug: nelfinavir

First Posted Date: 2008-06-11

Last Posted Date: 2015-04-10

Lead Sponsor: Maastricht Radiation Oncology

Target Recruit Count: 6

Registration Number: NCT00694837

Locations: 🇳🇱
Maastricht Radiation Oncology, Maastricht, Netherlands

A Study to Determine Effective Prophylaxis and Treatment of Nelfinavir-Associated Diarrhea

Phase 3

Terminated

Conditions: Diarrhea

Interventions: Drug: Calcium Carbonate
Other: Calcium carbonate not administered
Drug: nelfinavir
Drug: lamivudine + zidovudine
Drug: lamivudine
Drug: loperamide

First Posted Date: 2008-04-02

Last Posted Date: 2011-06-08

Lead Sponsor: Pfizer

Target Recruit Count: 17

Registration Number: NCT00650637

Locations: 🇺🇸
Pfizer Investigational Site, Houston, Texas, United States

Mechanisms of Lipodystrophy in HIV-Infected Pateints

Phase 4

Completed

Conditions: HIV Infections

Interventions: Drug: Efavirenz
Drug: Nelfinavir

First Posted Date: 2007-04-06

Last Posted Date: 2019-07-18

Lead Sponsor: University of Texas Southwestern Medical Center

Target Recruit Count: 56

Registration Number: NCT00457665

Locations: 🇺🇸
University of Texas Southwestern Medical Center, Dallas, Texas, United States

The Effects of HIV Protease Inhibitors in Severe Sepsis

Phase 1

Completed

Conditions: Sepsis

First Posted Date: 2006-06-30

Last Posted Date: 2011-04-05

Lead Sponsor: Mayo Clinic

Target Recruit Count: 60

Registration Number: NCT00346580

Locations: 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States

Determining the Amount of Time Needed for Nelfinavir to Boost the Immune System in Adults

Phase 1

Completed

Conditions: Immune Response

First Posted Date: 2006-06-30

Last Posted Date: 2010-01-20

Lead Sponsor: Mayo Clinic

Target Recruit Count: 25

Registration Number: NCT00346619

Locations: 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States

Thorough QT Study of Nelfinavir

Phase 4

Completed

Conditions: Healthy Volunteers

First Posted Date: 2006-04-07

Last Posted Date: 2009-04-10

Lead Sponsor: Pfizer

Target Recruit Count: 68

Registration Number: NCT00312182

Locations: 🇸🇬
Pfizer Investigational Site, Singapore, Singapore

Study to Determine the Pharmacokinetic Behavior of Antiretroviral Drugs in Patients Infected by HIV

Phase 1

Completed

Conditions: HIV Infections

Interventions: Drug: Nelfinavir
Drug: Saquinavir/ritonavir
Drug: Lopinavir/ritonavir
Drug: Atazanavir
Drug: Atazanavir/ritonavir
Drug: Fos-amprenavir/ritonavir
Drug: Tipranavir/ ritonavir
Drug: Darunavir/ritonavir
Drug: Nevirapine
Drug: Efavirenz
Drug: Indinavir/ritonavir

First Posted Date: 2006-03-28

Last Posted Date: 2019-12-04

Lead Sponsor: Germans Trias i Pujol Hospital

Target Recruit Count: 675

Registration Number: NCT00307502

Locations: 🇪🇸
Hospital de Figueres, Figueras, Barcelona, Spain
🇪🇸
Hospital Universitari Sant Joan de Reus, Reus, Tarragona, Spain
🇪🇸
Germans Trias i Pujol Hospital, Badalona, Barcelona, Spain

and more 3 locations

When to Start Anti-HIV Drugs in Children Infected With HIV (The PREDICT Study)

Phase 3

Completed

Conditions: HIV Infections

Interventions: Drug: Abacavir
Drug: Efavirenz
Drug: Lamivudine
Drug: Lopinavir/Ritonavir
Drug: Nelfinavir
Drug: Nevirapine
Drug: Zidovudine

First Posted Date: 2005-10-06

Last Posted Date: 2013-12-04

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 300

Registration Number: NCT00234091

Locations: 🇰🇭
National Pediatric Hosp., Cambodia CIPRA CRS, Phnom Penh, Cambodia
🇰🇭
Social Health Clinic, Cambodia CIPRA CRS, Phnom Penh, Cambodia
🇹🇭
Prapokklao Hosp. CIPRA CRS, Chantaburi, Thailand

and more 6 locations

Nelfinavir and M8 Drug-level Monitoring in HIV-1 Infection

Not Applicable

Completed

Conditions: HIV Infections

First Posted Date: 2005-09-20

Last Posted Date: 2019-03-22

Lead Sponsor: University of Wisconsin, Madison

Target Recruit Count: 20

Registration Number: NCT00205283

Locations: 🇺🇸
University of Wisconsin Hospital and Clinics, Madison, Wisconsin, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy